TY - JOUR A1 - Blümchen, Katharina A1 - Fischl, Anna A1 - Eiwegger, Thomas A1 - Hamelmann, Eckard A1 - Klimek, Ludger A1 - Lange, Lars A1 - Szépfalusi, Zsolt A1 - Vogelberg, Christian A1 - Beyer, Kirsten T1 - White paper peanut allergy: Part 3: management and therapy of peanut allergy T2 - Allergo journal international N2 - The current management of a primary IgE-mediated peanut allergy consists of the two basic pillars “exposure prophylaxis” with avoidance of the allergen and “emergency therapy” with short-term treatment of an acute allergic reaction after accidental ingestion. Accidental reactions are common despite attempted avoidance. The severity of an allergic or even anaphylactic reaction after accidental ingestion is difficult to assess prior to reaction. In addition, reaction thresholds may vary depending on the accompanying augmentation factor. Therefore, every peanut allergic patient should receive individual dietary counseling as well as instructions for the use of the emergency kit and a structured patient education program (anaphylaxis group training), if necessary. For the first time, since fall 2021 a causal treatment option with a drug for oral immunotherapy will now be available for 4‑ to 17-year-old peanut-allergic children and adolescents. The oral immunotherapy with peanut protein as defatted powder of Arachis hypogaea L., semen (peanuts) leads to desensitization with a good efficacy record and an acceptable safety profile. Other treatment options with different therapeutic approaches are also under development and will probably expand the range for treatment in the coming years. KW - Allergen avoidance KW - Accidental reaction KW - Oral immunotherapy KW - Epicutaneous immunotherapy KW - Anti-IgE Y1 - 2022 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/69539 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-695399 SN - 2197-0378 N1 - Open Access funding enabled and organized by Projekt DEAL. VL - 31 IS - 3 SP - 69 EP - 80 PB - Urban & Vogel CY - München ER -